DGAP-News: MOLOGEN AG

PRESS RELEASE N 15 / 2017 of 05/09/2017

MOLOGEN to present at ESMO 2017

Berlin, 5 September 2017 - The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present two posters on its lead compound, the immunotherapeutic agent lefitolimod, at the European Society for Medical Oncology (ESMO 2017) in Madrid (8 - 12 September 2017). The first poster is featuring top-line data from the exploratory phase II IMPULSE trial in small cell lung cancer patients; the respective abstract was selected as oral presentation in a Proffered Paper session during the congress. In a second poster, results of the combination of lefitolimod with checkpoint inhibitors in murine tumor models including data of the influence of lefitolimod on tumor microenvironment (TME) will be shown.

Abstract details:

1. Abstract number: 1527O
Title: "Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod"

Proffered Paper session: "Mesothelioma and SCLC" on 10 September 2017 from 9:15 - 10:45 am at the Barcelona Auditorium.
Chair(s): P. Garrido Lopez, ES; S. Popat, GB

2. Abstract number: 1642P
Titel: "The TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo"

Poster display session on 11 September 2017 from 13:15 - 14:15 in Hall 8.

For more information on ESMO 2017 please visit the website
HTTP://WWW.ESMO.ORG/CONFERENCES/ESMO-2017-CONGRESS
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical company and considered a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The immunotherapy lefitolimod (MGN1703) is the company's lead product and is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this action mechanism, lefitolimod (MGN1703) is an immune surveillance reactivator (ISR) and could potentially be used in various indications. The ISR lefitolimod (MGN1703) is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. The phase II IMPULSE study in small cell lung cancer is showing positive results in two previously defined and clinically relevant patient sub-groups, even though the primary endpoint "Overall Survival" in the overall study population was not met in this very challenging indication. Detailed analyses of IMPULSE data and the recently published TEACH data of the extension phase are currently being conducted. In addition, lefitolimod (MGN1703) is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. In tandem with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

www.mologen.com

Contact

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.